MRSN

Mersana Therapeutics (MRSN)

About Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Details

Daily high

$29.12

Daily low

$28.38

Price at open

$28.43

52 Week High

$53.00

52 Week Low

$5.21

Market cap

142.9M

Dividend yield

0.00%

Volume

61,948

Avg. volume

63,914

P/E ratio

-2.03

Mersana Therapeutics News